Contineum Therapeutics, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Contineum Therapeutics (market cap $102.1M) reported Q3 2026 net loss of $18.7M (vs. $12.8M in Q3 2025), with R&D expenses up 45% to $16.0M and G&A up 26% to $5.0M. Cash and marketable securities totaled $244.5M as of September 30, 2026, providing runway through mid-2029—sufficient to complete the PROPEL-IPF Phase 2 trial for PIPE-791 (IPF treatment), which has enrolled over 100 sites across 16 countries with ~324 patients targeted.
Why this rating
Clinical-stage biotech burning cash as expected; runway extension (mid-2029) is positive but routine for development phase. Loss increase and burn rate normal for program expansion. No material deal, regulatory setback, or milestone.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.